Latest Capital Raises News

Triangle Energy reports a solid cash position of $10.89 million as it prepares to drill the Becos-1 exploration well in early 2025, while managing ongoing transitions at the Cliff Head Oil Field and pursuing new ventures in the Philippines and UK.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Asset Vision Co Limited has reported a robust Q2 FY25, marked by significant revenue growth, improved cash flow, and effective cost management, positioning the company well for continued expansion.

Hawk Resources confirms significant near-surface copper mineralisation at its New Years prospect in Utah, alongside the identification of a dozen new exploration targets, setting the stage for an active 2025 drilling campaign.

Magmatic Resources has launched a 3,000m diamond drilling campaign at its Myall Project alongside encouraging soil sampling results at its Wellington North and Parkes projects, signaling advancing exploration momentum.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Rimfire Pacific Mining's December 2024 quarterly report reveals its highest-grade scandium intercept to date at Murga and strategic expansion with the Rabbit Trap Scandium Project acquisition, alongside promising cobalt-copper results at Broken Hill.

Top End Energy has taken a major step by acquiring the Kansas Natural Hydrogen Project and advancing its exploration footprint in Australia's Beetaloo Sub-Basin, positioning itself at the forefront of natural hydrogen and unconventional gas development.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Top End Energy Limited reported a net cash outflow in its December quarter, reducing its cash reserves to $2.76 million and leaving funding for just over two and a half quarters. The company’s cash flow dynamics highlight the ongoing financial pressures typical in early-stage oil and gas exploration.